Largos supervivientes y terapias dirigidas en melanoma avanzado - page 45

Trame +/- dabra + durvalumab

(NCT02027961)

BRAF

mutado

BRAF

normal

BRAF

normal

Durvalumab x 12 meses

Dabrafenib + Trametinib hasta prog.

Durvalumab x 12 meses

Trametinib hasta prog.

Durvalumab x 12 meses

Trametinib

x 6 sem.

Uso experimental, no autorizado

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1...,35,36,37,38,39,40,41,42,43,44 46